Table 5 |.

Key trials for the treatment of recurrent ovarian cancer

Study	Arms	Comments	Refs
Platinum-sensitive disease
ICON4/AGO-OVAR-2.2	Carboplatin	Increase in PFS and overall survival with the addition of paclitaxel	165
	Carboplatin and paclitaxel
OCEANS	Carboplatin, gemcitabine and bevacizumab with bevacizumab maintenance therapy	Increase in PFS with the addition of bevacizumab	226
	Carboplatin and gemcitabine
ICON6	Platinum-based chemotherapy and cediranib with cediranib maintenance therapy	Significant improvement in PFS Overall survival results are pending	177
	Platinum-based chemotherapy
NOVA	Platinum-based chemotherapy for platinum-sensitive recurrence followed by maintenance niraparib	Significant improvement in PFS with niraparib maintenance therapy compared with placebo, in women with germline BRCA mutations and women with homologous recombination deficiency	227
	Platinum-based chemotherapy for platinum-sensitive recurrence, followed by maintenance with placebo drug
NCT00113607	Pegylated liposomal doxorubicin and trabectedin	Significant increase in PFS with the addition of trabectedin	228
	Pegylated liposomal doxorubicin
NCT00753545	Platinum-based chemotherapy	Significant increase in PFS with olaparib maintenance therapy	229
	Platinum-based chemotherapy with olaparib maintenance therapy
NCT01081951	Carboplatin and paclitaxel	Increase in PFS with olaparib maintenance therapy	230
	Carboplatin and paclitaxel with olaparib maintenance therapy
NCT01116648	Olaparib	Increase in PFS when cediranib is added to olaparib compared with olaparib alone in patients with high-grade serous carcinoma	231
	Olaparib and cediranib
Platinum-resistant disease
AURELIA	Paclitaxel with or without bevacizumab	Increase in PFS and response rate with the addition of bevacizumab Paclitaxel plus bevacizumab was the best combination — increased response rate, PFS and overall survival	171, 172
	Pegylated liposomal doxorubicin with or without bevacizumab
	Topotecan with or without bevacizumab

PFS, progression-free survival.